Asymmetrex® Awarded $1.8M NIH-NHLBI SBIR Phase II Grant to Manufacture First Differential Tissue Stem Cell Counter
Summary
Our customer discovery interviews told us very clearly that the reason this long-needed method has not taken off, yet, is because it is not straightforward to perform, says James L. Sherley, M.D., Ph.D., Asymmetrexs President and CEO.Sherley decided to approach the National Heart, Lung, And Blood Institute for resources to address the convenience barrier. This September, his companys efforts were rewarded with a $1.8M Phase II Small Business Innovation Research grant to design and manufacture the first automated differential tissue stem cell counter. The content is solely the responsibility of the authors and does not necessarily represent official views of the National Institutes of Health.About AsymmetrexAsymmetrex, LLC is a U.S. life sciences company with a focus on developing technologies to advance stem cell medicine. The companys development of rapid differential stem cell counting technologies was funded previously by R&D grants from the National Heart, Lung, And Blood Institute and ARMI|BioFabUSA.EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article.